Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
STIM logo STIM
Upturn stock ratingUpturn stock rating
STIM logo

Neuronetics Inc (STIM)

Upturn stock ratingUpturn stock rating
$3.12
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/12/2025: STIM (4-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.5

1 Year Target Price $6.5

Analysts Price Target For last 52 week
$6.5 Target price
52w Low $0.52
Current$3.12
52w High $5.92

Analysis of Past Performance

Type Stock
Historic Profit 164.87%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 206.64M USD
Price to earnings Ratio -
1Y Target Price 6.5
Price to earnings Ratio -
1Y Target Price 6.5
Volume (30-day avg) 4
Beta 1.28
52 Weeks Range 0.52 - 5.92
Updated Date 09/14/2025
52 Weeks Range 0.52 - 5.92
Updated Date 09/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.15

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -43.92%
Operating Margin (TTM) -21.15%

Management Effectiveness

Return on Assets (TTM) -20.34%
Return on Equity (TTM) -190.79%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 276152062
Price to Sales(TTM) 1.86
Enterprise Value 276152062
Price to Sales(TTM) 1.86
Enterprise Value to Revenue 2.49
Enterprise Value to EBITDA -2.02
Shares Outstanding 66124800
Shares Floating 40965648
Shares Outstanding 66124800
Shares Floating 40965648
Percent Insiders 9.44
Percent Institutions 59.08

ai summary icon Upturn AI SWOT

Neuronetics Inc

stock logo

Company Overview

overview logo History and Background

Neuronetics, Inc. was founded in 2003. It is a medical technology company focused on developing and commercializing innovative, non-invasive neurostimulation therapies for patients suffering from neurological and psychiatric disorders. The company's primary focus has been on Transcranial Magnetic Stimulation (TMS) for the treatment of depression.

business area logo Core Business Areas

  • NeuroStar TMS Therapy System: Develops, manufactures, and markets the NeuroStar Advanced Therapy System, which delivers TMS therapy for the treatment of major depressive disorder (MDD).
  • Service and Support: Provides ongoing service, support, and training to clinics utilizing the NeuroStar system.

leadership logo Leadership and Structure

The leadership team typically includes a CEO, CFO, CMO, and other key executives. The organizational structure is hierarchical, with departments focused on research and development, manufacturing, sales and marketing, and clinical support.

Top Products and Market Share

overview logo Key Offerings

  • NeuroStar TMS Therapy System: NeuroStar is Neuronetics' primary product, a TMS system used to treat Major Depressive Disorder (MDD). While precise market share figures are difficult to obtain, Neuronetics is a significant player in the TMS therapy market. Competitors include Brainsway (BWAY), MagVenture, and CloudTMS. Reimbursement rates and clinical efficacy data drive adoption. Revenue is derived from system sales, per-procedure revenue, and service contracts.

Market Dynamics

industry overview logo Industry Overview

The neuromodulation market is growing, driven by an increasing prevalence of depression and a desire for non-pharmacological treatment options. TMS therapy is gaining acceptance as a viable alternative or adjunct to antidepressants.

Positioning

Neuronetics positions itself as a leading provider of TMS therapy for depression. Its competitive advantages include established brand recognition, clinical data supporting NeuroStar's efficacy, and a network of trained clinicians.

Total Addressable Market (TAM)

The TAM for depression treatment is substantial, encompassing millions of individuals. Neuronetics is positioned to capture a portion of this market through TMS therapy, with growth dependent on increasing awareness, adoption, and reimbursement coverage.

Upturn SWOT Analysis

Strengths

  • Established brand recognition in TMS
  • FDA clearance for NeuroStar
  • Extensive clinical data supporting efficacy
  • Large installed base of NeuroStar systems

Weaknesses

  • Limited product portfolio (primarily focused on TMS for depression)
  • Relatively high cost of TMS therapy
  • Dependence on reimbursement rates
  • Ongoing losses and need for financing

Opportunities

  • Expansion of TMS therapy into new indications (e.g., anxiety, OCD)
  • Development of next-generation TMS technology
  • Increased adoption of TMS therapy by psychiatrists and primary care physicians
  • Partnerships with mental health providers

Threats

  • Competition from other TMS systems and neuromodulation therapies
  • Changes in reimbursement policies
  • Negative publicity or safety concerns related to TMS
  • Economic downturn affecting patient affordability

Competitors and Market Share

competitor logo Key Competitors

  • BWAY
  • None

Competitive Landscape

Neuronetics faces competition from other TMS system manufacturers. The landscape is shaped by factors such as clinical efficacy, ease of use, cost, and reimbursement coverage.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been dependent on the adoption rates of NeuroStar TMS. Recent growth may have been tempered.

Future Projections: Future growth projections depend on factors like increasing TMS therapy adoption, new indications, and improvements in reimbursement.

Recent Initiatives: Recent initiatives include efforts to expand the use of NeuroStar in new settings, develop new marketing programs, and secure favorable reimbursement coverage.

Summary

Neuronetics, Inc. focuses on TMS therapy, primarily for depression. While they have an established brand, their growth depends on expanding adoption and securing favorable reimbursement. They face competition from other TMS providers and rely on future growth initiatives. Overall, the company is moderately strong, excelling in established TMS tech but needs diversification.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Neuronetics Investor Relations
  • SEC Filings
  • Industry Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate and subject to change. Financial data should be verified with official company filings.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Neuronetics Inc

Exchange NASDAQ
Headquaters Malvern, PA, United States
IPO Launch date 2018-06-28
President, CEO & Director Mr. Keith J. Sullivan
Sector Healthcare
Industry Medical Devices
Full time employees 716
Full time employees 716

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.